Home > Oncology > ESMO 2022 > OS benefit in ovarian cancer patients treated with maintenance olaparib

OS benefit in ovarian cancer patients treated with maintenance olaparib

Presented By
Dr Isabelle Ray-Coquard, Centre Léon Bérard, France
Conference
ESMO 2022
Trial
Phase 3, PAOLA-1
Addition of maintenance olaparib to bevacizumab provides a clinically meaningful overall survival (OS) benefit in patients who are HRD-positive, results from the final analysis of the PAOLA-1 trial show. Previously, results from the phase 3 PAOLA-1/ENGOT-ov25 trial (NCT02477644) showed clinical benefit of maintenance olaparib plus bevacizumab therapy in patients with newly diagnosed advanced ovarian cancer who had received first-line standard-of-care treatment including bevacizumab. Median progression-free survival (mPFS) was improved from 16.6 months with placebo/bevacizumab to 22.1. months with olaparib/bevacizumab (HR 0.59; P<0.001) [1]. In patients with tumours positive for homologous recombination deficiency (HRD), including tumours that had BRCA mutations, clinical benefit was even more pronounced (mPFS 37.2 vs 17.7 months; HR 0.33). Dr Isabelle ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on